RecruitingPhase 2Phase 3ACTRN12618001343291

Oxytocin's role in social cognitive changes in ageing

Examining the effects of acute administration of intranasal oxytocin on emotion recognition and related social cognitive functions in healthy ageing


Sponsor

Australian Catholic University

Enrollment

120 participants

Start Date

Jul 8, 2016

Study Type

Interventional

Conditions

Summary

The proposed research broadly aims to examine social cognitive changes and neuropeptide mechanisms in healthy older (vs. young) adults. This involves testing the effects of a small dose of acute intranasal OT (relative to placebo) on core social cognitive functions (e.g., emotion recognition, theory of mind), and to test if normal adult ageing is associated with changes in baseline levels of oxytocin and related hormones. We also explore whether individuals' level of functioning influence any of relationships between social cognition and oxytocin.


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 90 Yearss

Plain Language Summary

Simplified for easier understanding

Oxytocin — sometimes called the 'bonding hormone' — plays an important role in social behaviour, including recognising emotions and understanding what other people are thinking or feeling. As we age, these social cognitive abilities can change, and oxytocin levels in the body may shift too. This study is exploring whether a small dose of oxytocin given as a nasal spray affects how well people process social information, and whether ageing changes the baseline relationship between oxytocin and social cognition. Two groups will be recruited: young adults (18 to 30 years) and older adults (65 to 90 years). Each participant will receive a single dose of either oxytocin or a placebo nasal spray and then complete tests of emotion recognition and social understanding. Hormone levels will also be measured. You may be eligible if you are either aged 18 to 30 or 65 to 90, do not have any neurological or psychiatric conditions, are not currently taking antidepressants or antipsychotics, do not have heart disease, are not pregnant, and do not smoke. Older adults will also need to pass a brief telephone cognitive screening test.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

This study will administer an acute (single) dose of oxytocin (24 IU) nasal spray, once off. Administration of the nasal spray will be guided by the researcher on the day of testing to ensure consiste

This study will administer an acute (single) dose of oxytocin (24 IU) nasal spray, once off. Administration of the nasal spray will be guided by the researcher on the day of testing to ensure consistency in the administration of the intervention. Given the study involves a cross-over placebo-controlled design, there will be a washout period of approximately 4 weeks between active (oxytocin) and placebo testing sessions. The 4 weeks allow for the control of menstrual cycle effects in females.


Locations(1)

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12618001343291


Related Trials